Polaris Market Research Releases U.S. AI-Driven Diabetic Retinopathy Screening Market Outlook 2026-2034: Autonomous AI Drives Growth

New industry analysis projects a USD 1,081.73 Million U.S. AI-driven diabetic retinopathy screening market by 2034 as autonomous AI platforms, expanding CMS reimbursement, and primary care integration improve access to diabetic eye screening.

Market Size 2025	Forecast 2034	CAGR 2026-2034	Leading Region
USD 184.15 Million	USD 1,081.73 Million	21.74%	North America (36.35%)

Polaris Market Research & Consulting has released its U.S. AI-Driven Diabetic Retinopathy Screening Market Report 2026-2034. The market was valued at USD 184.15 million in 2025 and is projected to reach USD 1,081.73 million by 2034, registering a CAGR of 21.74% during the forecast period. Growth in the market is driven by the increasing number of patients with diabetes in the U.S., rising CMS payments for AI-based diabetic retinopathy screening, and growing use of AI retinal imaging technology in primary care.

The recent trends in the industry further adds up to the commercial viability of retinal screening with AI technology. In May 2026, Duke Eye Center became the pioneer of AI-powered diabetic retinopathy screening in the U.S. and introduced FDA-cleared autonomous AI screening into the endocrinology clinics. Prior to that, in October 2024, Eyenuk collaborated with the American Academy of Ophthalmology (AAO) to increase AI-based diabetic retinopathy screening among the underserved population in the EyeCare America program.

“AI-assisted screening for diabetic retinopathy has now become an integral part of preventive care in diabetes due to early detection, increased access from beyond specialist settings, and value-based care projects. Companies that integrate autonomous AI platforms which have been validated, ready for reimbursement, seamlessly integrated into workflow, and evidence-based will enhance their competitive advantage.” — Prajakta Bengale, Senior Healthcare Analyst

US AI Diabetic Retinopathy Screening Market Investment Signals 2026

Investment Theme	Market Signal	Business Implication
Primary Care Deployment	Duke Eye Center launched a large-scale AI-powered diabetic retinopathy screening program using FDA-cleared autonomous AI	Demonstrates growing adoption of point-of-care AI screening across primary and specialty care settings
CMS Reimbursement Expansion	CMS finalized the 2027 Medicare Advantage and Part D payment policies supporting reimbursement stability	Encourages broader investment in AI-based retinal screening programs across healthcare providers
Explainable AI Innovation	A March 2026 research study reported an explainable AI screening model with a 98.21% F1-score	Supports continued development of clinically interpretable AI systems for retinal disease detection
Community Screening Expansion	Eyenuk expanded AI-powered diabetic eye screening through its collaboration with the American Academy of Ophthalmology	Creates additional deployment opportunities across community and preventive care programs

Source: Polaris Market Research Analysis

Three trends Driving the Growth of the AI Diabetic Retinopathy Screening Market in the US for 2026

Primary Care is Moving towards the Center of AI Retinal Screening

Autonomous AI-driven retinal screening is increasingly incorporated into workflows by healthcare facilities in primary care and endocrinology settings. Screening at point of care helps increase access to diabetic eye examination, leads to early diagnosis, and decreases the need for specialty consultations.

CMS Reimbursement Is Supporting Commercial Adoption

Reimbursement assistance remains crucial in improving the financial justification of AI-based diabetic retinopathy screening. Stable reimbursement policies are encouraging hospitals, health systems, and primary care providers to integrate autonomous AI technologies into routine diabetes management and preventive care programs.

Explainable AI Is Advancing Clinical Confidence

Research focused on explainable artificial intelligence is improving transparency in AI-assisted retinal image analysis. As healthcare providers seek greater confidence in automated clinical decision support, explainable AI models are expected to play an increasingly important role in expanding adoption across routine screening programs

Request a free sample copy or read the full market insights : U.S. AI Diabetic Retinopathy Screening Market Report

About the Polaris US AI Diabetic Retinopathy Screening Market Report 2026-2034

The report provides comprehensive analysis of market size, segmentation, competitive landscape, technology developments, and reimbursement trends across the U.S. AI-driven diabetic retinopathy screening ecosystem. It is designed for AI diagnostics companies, healthcare systems, ophthalmology providers, payers, investors, government agencies, and digital health organizations seeking strategic insights into market opportunities, technology adoption, and competitive positioning.

Report coverage: Market size and CAGR by technology, care setting, and end user | State-level analysis across major U.S. markets | Competitive landscape and company benchmarking | Technology and innovation assessment | Reimbursement and regulatory environment analysis | PDF and Excel formats | Customization available by state, segment, and end user

Key Companies Profiled

AEYE Health Ltd.
Altris AI Inc.
Annexa Inc.
Digital Diagnostics Inc.
Eyenuk Inc.
Google Health (Verily Life Sciences LLC)
IDx Technologies Inc.
Optomed Plc
Retinal AI Ltd.
RetinaLyze A/S
Topcon Healthcare Inc.
Voxeleron LLC

Market Segments Covered in the US AI Diabetic Retinopathy Screening Market Report

By Technology Outlook (Revenue, USD Billion, 2021–2034)

Autonomous AI
Assistive AI
Cloud Image Analysis

By Care Setting Outlook (Revenue, USD Billion, 2021–2034)

Primary Care
Retail Clinics
Ophthalmology Networks
Federally Qualified Health Centers (FQHCs)
Other Care Settings

By End User Outlook (Revenue, USD Billion, 2021–2034)

Health Systems
Payers
Employers and Employer Health Plans
Public Programs (Medicaid, FQHC, IHS)
Others